



# **Tabelecleucel for Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease: Effectiveness and Value**

## **Questions for Deliberation and Voting: November 14th Public Meeting**

*These questions are intended for the deliberation of the New England CEPAC voting body at the public meeting.*

**Patient Population for all questions:** *People with relapsed/refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLN), who have received at least one prior therapy.*

### **Clinical Evidence**

1. Is the current evidence adequate to demonstrate that the net health benefit of tabelecleucel is superior to that provided by usual care?

Yes                  No

### **Benefits Beyond Health and Special Ethical Priorities**

**To help inform judgments of overall long-term value for money, please indicate your level of agreement with the following statements:**

1=Strongly Disagree; 2=Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree

2. There is substantial unmet need despite currently available treatments.
3. This condition is of substantial relevance for people from a racial/ethnic group who have not been equitably served by the healthcare system.

**To help inform judgments of overall long-term value for money, please indicate your level of agreement with the following statements based on the relative effects of tabelecleucel versus usual care:**

1=Strongly Disagree; 2=Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree

4. The treatment is likely to produce substantial improvement in caregivers' quality of life and/or ability to pursue their own education, work, and family life.
5. The treatment offers a substantial opportunity to improve access to effective treatment by means of its mechanism of action or method of delivery.

### **Long-Term Value for Money**

6. Given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering benefits beyond health and special ethical priorities, what is the long-term value for money of tabelecleucel compared to usual care at assumed pricing?\*

  - a. High long-term value for money at assumed pricing
  - b. Intermediate long-term value for money at assumed pricing
  - c. Low long-term value for money at assumed pricing

*\*This vote will only be taken if a price becomes available for tabelecleucel.*